Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran,Lisa G. Horvath,Tanya B. Dorff,Richard Greil,Jean-Pascal Machiels,Felicia Roncolato,Karen A. Autio,Matthew Rettig,Karim Fizazi,Martijn P. Lolkema,Anthony C. Fermin,Mark Salvati,Hosein Kouros-Mehr

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).

2020

Ben Tran
Lisa G. Horvath
Tanya B. Dorff
Richard Greil
Jean-Pascal Machiels
Felicia Roncolato
Karen A. Autio
Matthew Rettig
Karim Fizazi
Martijn P. Lolkema
Anthony C. Fermin
Mark Salvati
Hosein Kouros-Mehr

TPS261Background: AMG 160 is a novel HLE BiTE immune therapy that redirects T cells to kill tumor cells by binding to PSMA on tumor cells and CD3 on T cells. Methods: Primary objectives of this ope...

Keywords:

Cancer research
Castration
Prostate cancer
Pathology
Glutamate carboxypeptidase II
Immune system
T cell
Medicine
immune therapy
castration resistant
phase i study
in patient
CD3

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations